Opium Tincture Deodorized Tincture
FDA Recall NDC 42799-217

FDA Enforcement Report: View Recall Date, Reasons, and Safety Status

Active & Historical Enforcement Reports

The FDA has identified 1 recorded enforcement report(s) associated with Opium Tincture Deodorized (NDC 42799-217). A significant event, classified as Class III, was initiated on Oct 20, 2023 by Edenbridge Pharmaceuticals, Llc. The reported reason for this action was: "Subpotent Drug"

This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.

Reported Recall Events

October 2023 Class III Recall: Subpotent Drug

Recall Number
Class III Terminated
Reason for Recall
Subpotent Drug
Initiated
Oct 20, 2023
Reported
Nov 08, 2023
Quantity
4548 bottles

Recall Profile & Regulatory Data

Event ID
93236
Classification
Class III
Enforcement Status
Terminated
Recalling Firm
Edenbridge Pharmaceuticals, LLC
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide within the United States
Termination Date
Aug 16, 2024
Product Description
Opium Tincture, USP (Deodorized), 10 mg/mL of anhydrous morphine, packaged in 118 mL (4 Fl oz) bottles, Rx only, Manufactured for: Edenbridge Pharmaceuticals, LLC Parsippany, NJ 07054, NDC 42799-217-01
Batch or Lot Expiration Information
Lot# : 23ZCP1, Exp. Date 02/22/2026
Lot# :23ZDR1, Exp. Date 03/09/2026
Affected Packages Involved in this Recall
42799-217-01Product
42799-217-02Product

About FDA Recall Enforcement Reports

FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.

If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.